Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine versus placebo + azacitidine in newly diagnosed higher-risk myelodysplastic syndrome
2023-507153-16-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Venetoclax + azacitidine with Placebo + azacitidine (2 arms). Primary endpoint: Overall survival. Planned start Nov 2020; status: authorised.
02
Drugs
venetoclaxazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2023-507153-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507153-16-00.